Jingxin Fu

12PUBLICATIONS
149CO-AUTHORS
Liquid biopsiesMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jan 21, 2026
Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity.

Erica M Pimenta, Amanda E Garza, Sabrina Y Camp

|Nov 29, 2025
Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer.

Jingxin Fu, Adrienne G Waks, Erica Pimenta

|Nov 28, 2025
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial.

Adrienne G Waks, Jingxin Fu, Xiangying Chu

|Jul 02, 2025
Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma.

Chris Labaki, Eddy Saad, Katrine N Madsen

|Mar 02, 2025
Dissecting tumor cell programs through group biology estimation in clinical single-cell transcriptomics.

Shreya Johri, Kevin Bi, Breanna M Titchen

|Sep 08, 2023
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer.

Giacomo Oliveira, Ann Marie Egloff, Alexander B Afeyan

Pageof 2

Frequent Collaborators

5 joint publications

Eliezer M Van Allen

3 joint publications

Peng Jiang

3 joint publications

Jiexin Zhang

3 joint publications

Wubing Zhang